Why is this study being conducted?
Migraine is a common and debilitating medical condition that affects many people worldwide. Many of the current treatment options for migraine are often unsatisfactory. This study will evaluate the safety and effectiveness of a potential at-home treatment for migraine.
Who is eligible to participate in this study?
You may be eligible if you:
- Are between 18 and 65 years of age
- Have had 2 to 8 migraine attacks with moderate or severe pain per month for the last 3 months
- Have had migraine attacks present for at least 1 year
Applicants who express interest in participating in this study will be reviewed and contacted as other requirement criteria must also be met.
What happens during the study?
Trial duration will be up to 3 months and participants will have at least 3 trial visits
Trial site visits will occur at the Griffith University Clinical Trial Unit on the Gold Coast.
You will be assigned at random to receive either the study medication or placebo to treat one migraine episode at home.
You will attend the unit to receive a test dose of either the study medication or placebo prior to dosing at home.
Volunteer to participate
Participation in this study is completely voluntary, and participants can decide to withdraw at any time.
Eligible participants will be reimbursed for their time and travel associated with each study visit.
Contact Taryn Houghton/ Hannah Smith
For more information about this clinical trial contact:
Taryn Houghton/ Hannah Smith, Clinical Trial Coordinator.
0479 178 535 clinicaltrialunit@griffith.edu.au
This study has been approved by Bellberry Limited #2023-12-1518 and GU HREC #2025/698.
Can't see a trial for you?
Join our volunteer database to be contacted about new clinical trials